Search

Displaying results 4721 - 4730 of 10000 in total
  1. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    P-113D is a novel 12 amino-acid antimicrobial peptide drug derived from histatins, which are compounds found naturally in human saliva. It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

    Synonyms: D-PEPTIDE OF THE SEQUENCE AKRHHGYKRKFH - NH2
  2. Drug

    Solithromycin

    go.drugbank.com/drugs/DB09308
    Investigational

    Solithromycin is a ketolide antibiotic undergoing clinical development for the treatment of community-acquired pneumonia (CAP) and other infections.

  3. Drug

    Latamoxef

    go.drugbank.com/drugs/DB04570
    Approved

    Latamoxef is a broad- spectrum beta-lactam antibiotic similar in structure to the cephalosporins except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain cephalosporins

  4. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair.

  5. Drug

    Ocriplasmin

    go.drugbank.com/drugs/DB08888
    ApprovedWithdrawn

    Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. … Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved in October 17, 2012.

  6. Drug

    Cyclopentolate

    go.drugbank.com/drugs/DB00979
    Approved

    A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

  7. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  8. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. … AT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA.

  9. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.

  10. Drug

    KIN-3248

    go.drugbank.com/drugs/DB17587
    Investigational

    Therefore, the broad inhibition of FGFR isoforms may be effective against different types of tumors. … mutations in the kinase domain of FGFR.